Guangxi Wuzhou Zhongheng Group announced that its holding subsidiary Chongqing Lummy Pharmaceutical has received the "Pharmaceutical Registration Certificate" for Nimodipine Injection issued by the National Medical Products Administration. Nimodipine Injection is mainly used for the prevention and treatment of ischemic nerve damage caused by cerebral vasospasm after aneurysmal subarachnoid hemorrhage. The total research and development investment for Nimodipine Injection by Chongqing Lummy Pharmaceutical is 2.343 million RMB. From 2021 to 2023, the sales of Nimodipine Injection in the Chinese hospital market were 0.475 billion yuan, 0.421 billion yuan, and 0.347 billion yuan, respectively.
中恒集团：控股子公司莱美药业获尼莫地平注射液药品注册证书
Guangxi Wuzhou Zhongheng Group: Its holding subsidiary Chongqing Lummy Pharmaceutical has obtained the registration certificate for the pharmaceutical Nimodipine Injection.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated